MX2023010831A - Composiciones y metodos para tratar enfermedades neurologicas. - Google Patents
Composiciones y metodos para tratar enfermedades neurologicas.Info
- Publication number
- MX2023010831A MX2023010831A MX2023010831A MX2023010831A MX2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A MX 2023010831 A MX2023010831 A MX 2023010831A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- neurologic diseases
- treating neurologic
- treating
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con métodos para tratar enfermedades neurológicas, que comprenden administrar a un sujeto que lo necesita, una cantidad terapéuticamente eficaz de un compuesto o una composición farmacéutica de acuerdo con cualquier realización descrita en la presente. La presente invención se relaciona con métodos para tratar la enfermedad de Parkinson y la demencia con cuerpos de Lewy, que comprenden administrar a un sujeto que lo necesita, una cantidad terapéuticamente eficaz de un compuesto o una composición farmacéutica de acuerdo con cualquier realización descrita en la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163546P | 2021-03-19 | 2021-03-19 | |
| PCT/US2022/020687 WO2022197885A1 (en) | 2021-03-19 | 2022-03-17 | Compositions and methods for treating neurologic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010831A true MX2023010831A (es) | 2023-09-27 |
Family
ID=83320987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010831A MX2023010831A (es) | 2021-03-19 | 2022-03-17 | Composiciones y metodos para tratar enfermedades neurologicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240165077A1 (es) |
| EP (1) | EP4308565A1 (es) |
| JP (1) | JP2024510249A (es) |
| KR (1) | KR20230159546A (es) |
| CN (1) | CN117355525A (es) |
| AU (1) | AU2022239497A1 (es) |
| CA (1) | CA3212092A1 (es) |
| IL (1) | IL306063A (es) |
| MX (1) | MX2023010831A (es) |
| WO (1) | WO2022197885A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3634394A4 (en) * | 2017-05-15 | 2021-04-07 | Cognition Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP3704092A4 (en) * | 2017-11-01 | 2021-08-25 | Cognition Therapeutics, Inc. | ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE |
| CN110283082A (zh) * | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
-
2022
- 2022-03-17 MX MX2023010831A patent/MX2023010831A/es unknown
- 2022-03-17 JP JP2023556900A patent/JP2024510249A/ja active Pending
- 2022-03-17 CA CA3212092A patent/CA3212092A1/en active Pending
- 2022-03-17 WO PCT/US2022/020687 patent/WO2022197885A1/en active Application Filing
- 2022-03-17 EP EP22772183.4A patent/EP4308565A1/en active Pending
- 2022-03-17 CN CN202280035073.7A patent/CN117355525A/zh active Pending
- 2022-03-17 AU AU2022239497A patent/AU2022239497A1/en active Pending
- 2022-03-17 KR KR1020237035979A patent/KR20230159546A/ko unknown
- 2022-03-17 IL IL306063A patent/IL306063A/en unknown
- 2022-03-17 US US18/280,565 patent/US20240165077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230159546A (ko) | 2023-11-21 |
| AU2022239497A1 (en) | 2023-09-21 |
| IL306063A (en) | 2023-11-01 |
| JP2024510249A (ja) | 2024-03-06 |
| CN117355525A (zh) | 2024-01-05 |
| EP4308565A1 (en) | 2024-01-24 |
| WO2022197885A1 (en) | 2022-09-22 |
| US20240165077A1 (en) | 2024-05-23 |
| CA3212092A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| MX2020012180A (es) | Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina. | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
| PT1427708E (pt) | Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os | |
| TW200639159A (en) | Treatment of pain | |
| IL172419A0 (en) | Piperazine derivatives and methods of use | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| WO2005115432A3 (en) | Treatment of ocular diseases and disorders using lantibiotic compositions | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| EP4196113A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| CR20240003A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| NZ767228A (en) | Kv7 channel activators compositions and methods of use | |
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
| MXPA05011432A (es) | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. | |
| MX2023010831A (es) | Composiciones y metodos para tratar enfermedades neurologicas. | |
| WO2006101909A3 (en) | Combination therapy for treating or preventing diseases | |
| MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| KR102467285B9 (ko) | 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물 |